Related references
Note: Only part of the references are listed.Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
Markus Axelsson et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis
Tomas Kalincik et al.
BRAIN (2013)
Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers
Mohsen Khademi et al.
PLOS ONE (2013)
Neurofilaments as biomarkers in multiple sclerosis
Charlotte E. Teunissen et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Progressive multiple sclerosis: pathology and pathogenesis
Hans Lassmann et al.
NATURE REVIEWS NEUROLOGY (2012)
Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab
Martin Gunnarsson et al.
ANNALS OF NEUROLOGY (2011)
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
Mohsen Khademi et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
Carolina Holmen et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Age and disability accumulation in multiple sclerosis
A. Scalfari et al.
NEUROLOGY (2011)
Evidence for a two-stage disability progression in multiple sclerosis
Emmanuelle Leray et al.
BRAIN (2010)
Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test
A. S. Drake et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis
Emma C. Tallantyre et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks
S. A. Morrow et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
Michael Hutchinson et al.
JOURNAL OF NEUROLOGY (2009)
Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test
B. A. Parmenter et al.
MULTIPLE SCLEROSIS JOURNAL (2007)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Age at disability milestones in multiple sclerosis
C Confavreux et al.
BRAIN (2006)
Natural history of multiple sclerosis: a unifying concept
C Confavreux et al.
BRAIN (2006)
Share Paper
